LSE:CSRT

Stock Analysis Report

Executive Summary

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices in Europe, the United States, the United Kingdom, and internationally.

Snowflake

Fundamentals

Average dividend payer with moderate growth potential.


Similar Companies

Share Price & News

How has Consort Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.4%

CSRT

2.0%

GB Medical Equipment

-0.2%

GB Market


1 Year Return

-36.0%

CSRT

16.2%

GB Medical Equipment

-1.9%

GB Market

CSRT underperformed the Medical Equipment industry which returned 17.1% over the past year.

CSRT underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -0.9% over the past year.


Share holder returns

CSRTIndustryMarket
7 Day7.4%2.0%-0.2%
30 Day4.3%-1.2%3.5%
90 Day-10.3%12.2%0.6%
1 Year-33.4%-36.0%18.8%16.2%2.9%-1.9%
3 Year-23.7%-28.5%52.9%44.8%20.7%6.2%
5 Year0.2%-21.0%89.2%72.6%33.6%5.4%

Price Volatility Vs. Market

How volatile is Consort Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

8 months ago | Simply Wall St

How Much Money Does Consort Medical plc (LON:CSRT) Make?

Valuation

Is Consort Medical undervalued based on future cash flows and its price relative to the stock market?

0.229%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Consort Medical's share price is below the future cash flow value, but not at a moderate discount (< 20%).

Consort Medical's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Consort Medical is overvalued based on earnings compared to the GB Medical Equipment industry average.

Consort Medical is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.


Price Based on Expected Growth

Consort Medical is poor value based on expected growth next year.


Price Based on Value of Assets

Consort Medical is good value based on assets compared to the GB Medical Equipment industry average.


Next Steps

Future Growth

How is Consort Medical expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

25.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Consort Medical's revenue is expected to grow by 3.3% yearly, however this is not considered high growth (20% yearly).

Consort Medical's earnings are expected to grow significantly at over 20% yearly.

Consort Medical's revenue growth is positive but not above the United Kingdom of Great Britain and Northern Ireland market average.

Consort Medical's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.

Consort Medical's earnings growth is expected to exceed the low risk savings rate of 1.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Consort Medical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Consort Medical performed over the past 5 years?

9.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Consort Medical's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.

Consort Medical's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Consort Medical's 1-year earnings growth is negative, it can't be compared to the GB Medical Equipment industry average.


Return on Equity

Consort Medical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Consort Medical used its assets less efficiently than the GB Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Consort Medical's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Consort Medical's financial position?


Financial Position Analysis

Consort Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Consort Medical's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Consort Medical's level of debt (46.6%) compared to net worth is high (greater than 40%).

Unable to establish if Consort Medical's debt level has increased without past 5-year debt data.

Debt is well covered by operating cash flow (31.2%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 12.4x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.2x debt.


Next Steps

Dividend

What is Consort Medical's current dividend yield, its reliability and sustainability?

2.99%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Consort Medical's pays a higher dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.02%).

Consort Medical's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (5.44%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are not well covered by earnings (1x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (3.1x coverage).


Next Steps

Management

What is the CEO of Consort Medical's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Jon Glenn (50yo)

11.8yrs

Tenure

UK£1,146,000

Compensation

Mr. Jonathan M. Glenn, also known as Jon, has been the Chief Executive Offer of Consort Medical Plc at Bespak Europe Ltd. since December 5, 2007. Mr. Glenn has been a Director at Atlas Genetics Ltd. since ...


CEO Compensation Analysis

Jon's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.

Jon's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.7yrs

Average Tenure

The average tenure for the Consort Medical management team is less than 2 years, this suggests a new team.


Board Age and Tenure

6.2yrs

Average Tenure

54yo

Average Age

The tenure for the Consort Medical board of directors is about average.


Insider Trading

More shares have been bought than sold by Consort Medical individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyUK£9,93612 Aug 19
Ian Nicholson
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares1,350
Max PriceUK£7.36
BuyUK£7,31906 Aug 19
Christopher Brinsmead
EntityIndividual
Role
Chairman of the Board
Chairman
Shares1,000
Max PriceUK£7.32
BuyUK£30,49506 Dec 18
Paul Hayes
EntityIndividual
Role
Member of the Board of Directors
CFO & Executive Director
Shares4,000
Max PriceUK£7.66

Ownership Breakdown


Management Team

  • Jon Glenn (50yo)

    CEO & Director

    • Tenure: 11.8yrs
    • Compensation: UK£1.15m
  • Colin Leeder

    Group Financial Controller

    • Tenure: 0yrs
  • Lisa King

    Director of Human Resources

    • Tenure: 11.1yrs
  • Keyvan Djamarani

    Business President of Bespak Drug Delivery Devices

    • Tenure: 1.7yrs
  • Paul Hayes (52yo)

    CFO & Executive Director

    • Tenure: 2.3yrs
    • Compensation: UK£635.00k
  • Andrew Jackson

    Group General Counsel & Company Secretary

    • Tenure: 1.1yrs
  • Manja Boerman

    Business President of Aesica Development & Manufacture API and Finished Dose

    • Tenure: 1.7yrs
  • Kevin Cunningham

    Vice President of Operations

    • Tenure: 0.7yrs

Board Members

  • William Jenkins (72yo)

    Senior Independent Director

    • Tenure: 8yrs
    • Compensation: UK£66.16k
  • Ian Nicholson (59yo)

    Non-Executive Director

    • Tenure: 7.3yrs
    • Compensation: UK£47.22k
  • Steve Crummett (54yo)

    Non-Executive Director

    • Tenure: 7.3yrs
    • Compensation: UK£50.13k
  • Drew Hosty (54yo)

    Non Executive Director

    • Tenure: 5.2yrs
    • Compensation: UK£44.51k
  • Jon Glenn (50yo)

    CEO & Director

    • Tenure: 11.8yrs
    • Compensation: UK£1.15m
  • Chris Brinsmead (60yo)

    Chairman

    • Tenure: 0.4yrs
    • Compensation: UK£12.02k
  • Paul Hayes (52yo)

    CFO & Executive Director

    • Tenure: 2.3yrs
    • Compensation: UK£635.00k
  • Maria Ginman-Horrell (53yo)

    Non-Executive Director

    • Tenure: 4.6yrs
    • Compensation: UK£42.03k

Company Information

Consort Medical plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Consort Medical plc
  • Ticker: CSRT
  • Exchange: LSE
  • Founded: 1946
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£383.752m
  • Shares outstanding: 49.07m
  • Website: https://www.consortmedical.com

Number of Employees


Location

  • Consort Medical plc
  • Breakspear Park
  • Suite B
  • Hemel Hempstead
  • Hertfordshire
  • HP2 4TZ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CSRTLSE (London Stock Exchange)YesOrdinary SharesGBGBPJan 1992
8C7BST (Boerse-Stuttgart)YesOrdinary SharesDEEURJan 1992
CSRTlBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPJan 1992

Biography

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices in Europe, the United States, the United Kingdom, and internationally. It operates through t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 20:41
End of Day Share Price2019/09/20 00:00
Earnings2019/04/30
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.